CA2391362A1 - Identification specifique au serotype de l'enterovirus 71 par rt-pcr - Google Patents
Identification specifique au serotype de l'enterovirus 71 par rt-pcr Download PDFInfo
- Publication number
- CA2391362A1 CA2391362A1 CA002391362A CA2391362A CA2391362A1 CA 2391362 A1 CA2391362 A1 CA 2391362A1 CA 002391362 A CA002391362 A CA 002391362A CA 2391362 A CA2391362 A CA 2391362A CA 2391362 A1 CA2391362 A1 CA 2391362A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- nucleic acid
- nucleotide sequence
- primer
- same
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241001529459 Enterovirus A71 Species 0.000 title claims abstract description 183
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 230
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 218
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 218
- 230000003321 amplification Effects 0.000 claims abstract description 70
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 70
- 238000000034 method Methods 0.000 claims abstract description 66
- 238000012163 sequencing technique Methods 0.000 claims abstract description 28
- 125000003729 nucleotide group Chemical group 0.000 claims description 117
- 239000002773 nucleotide Substances 0.000 claims description 115
- 230000000295 complement effect Effects 0.000 claims description 14
- 239000011541 reaction mixture Substances 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 abstract description 36
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 abstract description 20
- 108020004705 Codon Proteins 0.000 abstract description 15
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 239000013615 primer Substances 0.000 description 232
- 108020004414 DNA Proteins 0.000 description 57
- 241001429382 Coxsackievirus A16 Species 0.000 description 35
- 108091028043 Nucleic acid sequence Proteins 0.000 description 24
- 239000000523 sample Substances 0.000 description 23
- 229930010555 Inosine Natural products 0.000 description 20
- 229960003786 inosine Drugs 0.000 description 20
- 238000003752 polymerase chain reaction Methods 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- 238000006467 substitution reaction Methods 0.000 description 19
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 18
- 241000709661 Enterovirus Species 0.000 description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
- 238000001514 detection method Methods 0.000 description 13
- 238000003757 reverse transcription PCR Methods 0.000 description 13
- 201000009906 Meningitis Diseases 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 12
- 238000009396 hybridization Methods 0.000 description 12
- 101150024766 VP1 gene Proteins 0.000 description 11
- 238000000137 annealing Methods 0.000 description 11
- 238000010839 reverse transcription Methods 0.000 description 11
- 241000894007 species Species 0.000 description 11
- 206010033799 Paralysis Diseases 0.000 description 10
- 241000700605 Viruses Species 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 238000002955 isolation Methods 0.000 description 9
- 241000991587 Enterovirus C Species 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000003155 DNA primer Substances 0.000 description 7
- 208000010201 Exanthema Diseases 0.000 description 7
- 208000020061 Hand, Foot and Mouth Disease Diseases 0.000 description 7
- 208000025713 Hand-foot-and-mouth disease Diseases 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 201000005884 exanthem Diseases 0.000 description 7
- 206010037844 rash Diseases 0.000 description 7
- 102100034343 Integrase Human genes 0.000 description 6
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 6
- VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 5
- 208000000474 Poliomyelitis Diseases 0.000 description 5
- 102100037968 Ribonuclease inhibitor Human genes 0.000 description 5
- 108020000999 Viral RNA Proteins 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 208000015114 central nervous system disease Diseases 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000004590 computer program Methods 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- -1 nucleoside triphosphates Chemical class 0.000 description 4
- 239000002987 primer (paints) Substances 0.000 description 4
- 235000011178 triphosphate Nutrition 0.000 description 4
- 239000001226 triphosphate Substances 0.000 description 4
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 238000002820 assay format Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 3
- 229960005542 ethidium bromide Drugs 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000011392 neighbor-joining method Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 108020001019 DNA Primers Proteins 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 2
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241001207270 Human enterovirus Species 0.000 description 2
- 238000007476 Maximum Likelihood Methods 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- DCHQYSOGURGJST-FJXKBIBVSA-N Pro-Thr-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O DCHQYSOGURGJST-FJXKBIBVSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 108010024226 placental ribonuclease inhibitor Proteins 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- UQJUGHFKNKGHFQ-VZFHVOOUSA-N Ala-Cys-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UQJUGHFKNKGHFQ-VZFHVOOUSA-N 0.000 description 1
- 208000006740 Aseptic Meningitis Diseases 0.000 description 1
- 241000713838 Avian myeloblastosis virus Species 0.000 description 1
- 101100166838 Caenorhabditis elegans ces-2 gene Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000146303 Coxsackievirus A1 Species 0.000 description 1
- 208000019736 Cranial nerve disease Diseases 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 241000134257 Echovirus E30 Species 0.000 description 1
- 241000217436 Echovirus E32 Species 0.000 description 1
- 206010014909 Enterovirus infection Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 235000004863 Fevillea cordifolia Nutrition 0.000 description 1
- 244000034902 Fevillea cordifolia Species 0.000 description 1
- 208000014770 Foot disease Diseases 0.000 description 1
- 241001123946 Gaga Species 0.000 description 1
- SITLTJHOQZFJGG-XPUUQOCRSA-N Glu-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(O)=O SITLTJHOQZFJGG-XPUUQOCRSA-N 0.000 description 1
- 241000726306 Irus Species 0.000 description 1
- NHHKSOGJYNQENP-SRVKXCTJSA-N Leu-Cys-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)O)N NHHKSOGJYNQENP-SRVKXCTJSA-N 0.000 description 1
- YWKNKRAKOCLOLH-OEAJRASXSA-N Leu-Phe-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CC1=CC=CC=C1 YWKNKRAKOCLOLH-OEAJRASXSA-N 0.000 description 1
- 206010027201 Meningitis aseptic Diseases 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000754835 Sapovirus isolates Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- KDGBLMDAPJTQIW-RHYQMDGZSA-N Thr-Met-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)O)N)O KDGBLMDAPJTQIW-RHYQMDGZSA-N 0.000 description 1
- 101150036700 VP3 gene Proteins 0.000 description 1
- SWPYNTWPIAZGLT-UHFFFAOYSA-N [amino(ethoxy)phosphanyl]oxyethane Chemical compound CCOP(N)OCC SWPYNTWPIAZGLT-UHFFFAOYSA-N 0.000 description 1
- CUJRVFIICFDLGR-UHFFFAOYSA-N acetylacetonate Chemical compound CC(=O)[CH-]C(C)=O CUJRVFIICFDLGR-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 108010036533 arginylvaline Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000010460 detection of virus Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 108010003700 lysyl aspartic acid Proteins 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 238000002862 phylogeny inference package Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000000772 tip-enhanced Raman spectroscopy Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
L'invention concerne des acides nucléiques pouvant être utilisés comme amorces dans des réactions d'amplification ou de séquençage visant, respectivement, à amplifier ou à séquencer rapidement des acides nucléiques EV71. Un groupe préféré d'acides nucléiques, lorsqu'il est utilisé comme paires d'amorces dans des réactions d'amplification, détecte EV71 avec une spécificité et une sensibilité importantes. Grâce à ces paires préférées d'amorces, la spécificité des procédés d'amplification est telle que l'acide nucléique EV71 est amplifié à un niveau détectable, tandis que l'ADN CA16 ne l'est pas. Les amorces d'acide nucléique de la présente invention contiennent des bases mixtes ou des restes de déoxyinosine à des positions de dégénérescence de codons. Des exemples d'amorces d'acide nucléique pour l'amplification et le séquençage de l'acide EV71 sont illustrés dans la liste des séquences sous SEQ ID NOS : 1-12. Des exemples d'amorces préférées pour la discrimination entre EV71 et CA16 sont illustrés dans la liste des séquences sous SEQ ID NOS : 1-4.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16452099P | 1999-11-10 | 1999-11-10 | |
| US60/164,520 | 1999-11-10 | ||
| PCT/US2000/029021 WO2001034848A2 (fr) | 1999-11-10 | 2000-10-20 | Identification specifique au serotype de l'enterovirus 71 par rt-pcr |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2391362A1 true CA2391362A1 (fr) | 2001-05-17 |
Family
ID=22594878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002391362A Abandoned CA2391362A1 (fr) | 1999-11-10 | 2000-10-20 | Identification specifique au serotype de l'enterovirus 71 par rt-pcr |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1230399A2 (fr) |
| AU (1) | AU1219301A (fr) |
| CA (1) | CA2391362A1 (fr) |
| WO (1) | WO2001034848A2 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003014397A1 (fr) * | 2001-08-09 | 2003-02-20 | Biomedlab Corporation | Sonde destinee a la detection de virus enteriques, kit de detection et procede de detection de virus enteriques |
| CN101812535B (zh) * | 2009-02-24 | 2012-08-22 | 江苏默乐生物科技有限公司 | 肠道病毒ev71检测特异性引物和探针 |
| CN101812538B (zh) * | 2009-11-13 | 2012-01-04 | 镇江市疾病预防控制中心 | 一种检测肠道病毒71型的荧光定量rt-pcr试剂盒 |
| WO2012060779A1 (fr) * | 2010-11-02 | 2012-05-10 | Singapore Polytechnic | Méthode de détection de l'entérovirus ev71 |
| CN106520789B (zh) * | 2015-09-09 | 2019-05-10 | 中国人民解放军军事医学科学院微生物流行病研究所 | 一种dna分子与重组病毒及它们的制备方法和用途 |
| CN114540548A (zh) * | 2022-02-28 | 2022-05-27 | 贵州安康医学检验中心有限公司 | 一种基于多交叉恒温扩增和金纳米生物传感器 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6168917B1 (en) * | 1996-10-02 | 2001-01-02 | The United States Of America As Represented By The Department Of Health And Human Services | Detection and identification of non-polio enteroviruses |
| EP1218548B1 (fr) * | 1999-03-31 | 2005-05-11 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by The Secretary, Department of Health and Human Services | Typage d'enterovirus humains |
-
2000
- 2000-10-20 AU AU12193/01A patent/AU1219301A/en not_active Abandoned
- 2000-10-20 WO PCT/US2000/029021 patent/WO2001034848A2/fr not_active Ceased
- 2000-10-20 CA CA002391362A patent/CA2391362A1/fr not_active Abandoned
- 2000-10-20 EP EP00973713A patent/EP1230399A2/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU1219301A (en) | 2001-06-06 |
| EP1230399A2 (fr) | 2002-08-14 |
| WO2001034848A2 (fr) | 2001-05-17 |
| WO2001034848A3 (fr) | 2002-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2370169T3 (es) | Composiciones y métodos para detectar el virus de la hepatitis b. | |
| US5283171A (en) | Compositions for and detection of human papillomavirus by specific oligonucleotide polymerase primers using the polymerase chain reaction | |
| AU775950B2 (en) | Typing of human enteroviruses | |
| US20100279273A1 (en) | Nucleic acid sequences for the amplification and detection of respiratory viruses | |
| CA2525413C (fr) | Compositions, methodes et kits de detection de la presence de trichomonas vaginalis dans un echantillon d'essai | |
| AU693465B2 (en) | Poliovirus specific primers and methods of detection utilizing the same | |
| ES2300375T3 (es) | Composiciones y metodos para la deteccion del virus de la inmunodeficiencia humana 2 (hiv-2). | |
| HK1042323B (en) | Identification of microorganisms causing acute respiratory tract infections (ari) | |
| ES2380115T3 (es) | Procedimiento para la detección de HPV, y sondas, cebadores y kits | |
| US6168917B1 (en) | Detection and identification of non-polio enteroviruses | |
| CA2391362A1 (fr) | Identification specifique au serotype de l'enterovirus 71 par rt-pcr | |
| US20020142293A1 (en) | Enteroviral polynucleotides, methods of detecting enteroviruses and kits containing the polynucleotides | |
| WO2000037672A1 (fr) | Reaction en chaine de la polymerase quantitative utilisant un systeme de detection en temps reel | |
| Verbeek et al. | Polymerase chain reaction for probe synthesis and for direct amplification in detection of bovine coronavirus | |
| EP1591544A1 (fr) | Detection d'acide nucléique d'entérovirus | |
| WO2003000887A1 (fr) | Sonde polynucleotidique et amorce originaire du virus de l'hepatite e des japonais, puces pourvues de cette sonde, kits dotes de cette sonde et procede pour detecter le virus de l'hepatite e au moyen de cette sonde | |
| JPH05276996A (ja) | コレラ毒素産生菌検出用オリゴヌクレオチド、コレラ毒素産生菌の検出法及び検出用試薬キット | |
| WO1999053096A2 (fr) | Acides nucleiques specifiques du serotype du poliovirus et procedes servant a detecter des serotypes specifiques du poliovirus | |
| CA2547750A1 (fr) | Compositions, methodes et trousses destinees a la detection des acides nucleiques du vih 1 et du vih 2 | |
| JPH04504803A (ja) | Ｈｈｖ／ｓｉｅゲノムから誘導された核酸断片と診断試薬及びｈｈｖ６感染の診断法 | |
| Chapman et al. | Identification of coxsackie B viruses and enteroviruses in general using nucleic acid hybridization | |
| JP3016994B2 (ja) | Ｃ群ロタウイルス検出用ヌクレオチド、ｃ群ロタウイルス検出法およびｃ群ロタウイルス検出用試薬キット | |
| ES2349543T3 (es) | Composiciones, métodos y equipos para la detección de ácidos nucleicos del vih-1 y vih-2. | |
| Mixed-Base | Serotype-Specific Identification of Polioviruses | |
| CA2503468A1 (fr) | Detection et identification d'enterovirus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |